Cargando…
Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
Vaccination programs against SARS-CoV-2 constitute the mainstay of public health interventions against the global COVID-19 pandemic. Currently available vaccines have shown 90% or better rates of protection against severe disease and mortality. Barely a year after vaccines became available, the Omic...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928742/ https://www.ncbi.nlm.nih.gov/pubmed/35313532 http://dx.doi.org/10.1016/j.metop.2022.100180 |
_version_ | 1784670705732812800 |
---|---|
author | Amanatidou, Evropi Gkiouliava, Anna Pella, Eva Serafidi, Maria Tsilingiris, Dimitrios Vallianou, Natalia G. Karampela, Irene Dalamaga, Maria |
author_facet | Amanatidou, Evropi Gkiouliava, Anna Pella, Eva Serafidi, Maria Tsilingiris, Dimitrios Vallianou, Natalia G. Karampela, Irene Dalamaga, Maria |
author_sort | Amanatidou, Evropi |
collection | PubMed |
description | Vaccination programs against SARS-CoV-2 constitute the mainstay of public health interventions against the global COVID-19 pandemic. Currently available vaccines have shown 90% or better rates of protection against severe disease and mortality. Barely a year after vaccines became available, the Omicron variant and its unprecedented speed of transmission has posed a new challenge. Overall, Omicron presents increased immune escape, transmissibility, and decreased pathogenicity. Vaccines do not offer a full protection against SARS-CoV-2 acquisition, since “breakthrough” infections may occur in fully vaccinated individuals, who may in turn spread the virus to others. Breakthrough infections may be causally related to the viral profile (viral variant and load, incubation period, transmissibility, pathogenicity, immune evasion), immunity characteristics (mucosal versus systemic immunity, duration of immunity, etc.), host determinants (age, comorbidities, immune status, immunosuppressive drugs) and vaccination properties (platform, antigen dose, dose number, dose interval, route of administration). Determining the rate of breakthrough infections may be challenging and necessitates the conduction of population-based studies regarding vaccine effectiveness as well as neutralizing antibody testing, a surrogate of immune protection. In this review, we analyze the causes of breakthrough infections, their clinical consequences (severity of infection and transmission), methods of determining their incidence as well as challenges and perspectives. Long COVID as well as multi-inflammatory syndrome in adolescents may be significantly reduced in breakthrough infections. The need for universal pancoranavirus vaccines that would aim at protecting against a plethora of SARS-CoV-2 variants as well as emerging variants is discussed. Finally, novel vaccine strategies, such as nasal vaccines, may confer robust mucosal and systemic protection, reducing efficiently transmission. |
format | Online Article Text |
id | pubmed-8928742 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-89287422022-03-17 Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges Amanatidou, Evropi Gkiouliava, Anna Pella, Eva Serafidi, Maria Tsilingiris, Dimitrios Vallianou, Natalia G. Karampela, Irene Dalamaga, Maria Metabol Open Articles from the Vaccines, Immune Response, Therapeutic Interventions and COVID-19 Special Issue Vaccination programs against SARS-CoV-2 constitute the mainstay of public health interventions against the global COVID-19 pandemic. Currently available vaccines have shown 90% or better rates of protection against severe disease and mortality. Barely a year after vaccines became available, the Omicron variant and its unprecedented speed of transmission has posed a new challenge. Overall, Omicron presents increased immune escape, transmissibility, and decreased pathogenicity. Vaccines do not offer a full protection against SARS-CoV-2 acquisition, since “breakthrough” infections may occur in fully vaccinated individuals, who may in turn spread the virus to others. Breakthrough infections may be causally related to the viral profile (viral variant and load, incubation period, transmissibility, pathogenicity, immune evasion), immunity characteristics (mucosal versus systemic immunity, duration of immunity, etc.), host determinants (age, comorbidities, immune status, immunosuppressive drugs) and vaccination properties (platform, antigen dose, dose number, dose interval, route of administration). Determining the rate of breakthrough infections may be challenging and necessitates the conduction of population-based studies regarding vaccine effectiveness as well as neutralizing antibody testing, a surrogate of immune protection. In this review, we analyze the causes of breakthrough infections, their clinical consequences (severity of infection and transmission), methods of determining their incidence as well as challenges and perspectives. Long COVID as well as multi-inflammatory syndrome in adolescents may be significantly reduced in breakthrough infections. The need for universal pancoranavirus vaccines that would aim at protecting against a plethora of SARS-CoV-2 variants as well as emerging variants is discussed. Finally, novel vaccine strategies, such as nasal vaccines, may confer robust mucosal and systemic protection, reducing efficiently transmission. Elsevier 2022-03-17 /pmc/articles/PMC8928742/ /pubmed/35313532 http://dx.doi.org/10.1016/j.metop.2022.100180 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Articles from the Vaccines, Immune Response, Therapeutic Interventions and COVID-19 Special Issue Amanatidou, Evropi Gkiouliava, Anna Pella, Eva Serafidi, Maria Tsilingiris, Dimitrios Vallianou, Natalia G. Karampela, Irene Dalamaga, Maria Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges |
title | Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges |
title_full | Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges |
title_fullStr | Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges |
title_full_unstemmed | Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges |
title_short | Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges |
title_sort | breakthrough infections after covid-19 vaccination: insights, perspectives and challenges |
topic | Articles from the Vaccines, Immune Response, Therapeutic Interventions and COVID-19 Special Issue |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928742/ https://www.ncbi.nlm.nih.gov/pubmed/35313532 http://dx.doi.org/10.1016/j.metop.2022.100180 |
work_keys_str_mv | AT amanatidouevropi breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges AT gkiouliavaanna breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges AT pellaeva breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges AT serafidimaria breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges AT tsilingirisdimitrios breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges AT vallianounataliag breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges AT karampelairene breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges AT dalamagamaria breakthroughinfectionsaftercovid19vaccinationinsightsperspectivesandchallenges |